Skip to Content

Indium In 111 Pentetreotide use while Breastfeeding

Medically reviewed on November 7, 2017

Indium In 111 Pentetreotide Levels and Effects while Breastfeeding

Summary of Use during Lactation

Information in this record refers to the use of indium In 111 pentetreotide as a diagnostic agent. The International Commission on Radiological Protection states that breastfeeding need not be interrupted following diagnostic use of In 111 pentetreotide.[1]

In some cases, imaging with indium In 111 pentetreotide is followed shortly by a therapy (peptide receptor radiotherapy; PRRT) that uses yttrium 90 or lutetium 177 compounds to selectively irradiate tumors. These agents may pose additional radiation risk to the nursing infant.

Mothers concerned about the level of radioactivity in their milk could ask to have it tested at a nuclear medicine facility at their hospital. When the radioactivity is at a safe level she may resume breastfeeding. A method for measuring milk radioactivity and determining the time when a mother can safely resume breastfeeding has been published.[2]

Drug Levels

In 111 decays by electron capture with 171 and 245 keV gamma emissions and a physical half-life of 2.8 days.[3] The biological half-life of indium In-111 pentetreotide is 6 hours.[4]

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.


1. Balon HR, Brown TL, Goldsmith SJ et al. The SNM practice guideline for somatostatin receptor scintigraphy 2.0. J Nucl Med Technol. 2011;39:317-24. PMID: 22068564

2. Stabin MG, Breitz HB. Breast milk excretion of radiopharmaceuticals: mechanisms, findings, and radiation dosimetry. J Nucl Med. 2000;41:863-73. PMID: 10809203

3. Howe DB, Beardsley M, Bakhsh S. Appendix U. Model procedure for release of patients or human research subjects administered radioactive materials. In, NUREG-1556. Consolidated guidance about materials licenses. Program-specific guidance about medical use licenses. Final report. U.S. Nuclear Regulatory Commission Office of Nuclear Material Safety and Safeguards. 2008;9, Rev. 2.

4. Mallinckrodt Inc. OctreoScan product information. 2006;October 25.

Indium In 111 Pentetreotide Identification

Substance Name

Indium In 111 Pentetreotide

CAS Registry Number


Drug Class


Indium Radioisotopes

Administrative Information

LactMed Record Number



Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.